SW-1115C3 is under clinical development by Stemirna Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SW-1115C3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SW-1115C3 overview
SW-1115C3 is under development for the treatment of advanced esophageal squamous carcinoma, non-small cell cancer, pancreatic cancer, colorectal adenocarcinoma, gastric adenocarcinoma and pancreatic adenocarcinoma. It is administered through subcutaneous route. It is developed based on the mRNA vaccines platform. The therapeutic candidate is a personalized vaccine comprises of mRNA encoding for tumor specific antigens.
See Also:
Stemirna Therapeutics overview
Stemirna Therapeutics (Stemirna) is a biotechnology company that discovers and develops drugs for mRNA therapeutics, immuno-oncology and nanoparticle formulation. Stemirna is headquartered in Shanghai, China.
For a complete picture of SW-1115C3’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
